STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRSP
  4. [Form 4] CRISPR Therapeutics AG Insider Trading Activity

CRSP insider files Form 4: 1,076 shares sold to cover taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CRISPR Therapeutics (CRSP) reported an insider equity event. The company’s General Counsel and Secretary had 2,114 restricted stock units settle into common shares on 10/13/2025. On 10/14/2025, 1,076 shares were sold at $66.6 to cover tax withholding under the company’s RSU Settlement Policy, described as a non-discretionary sale.

Following these transactions, the insider directly owned 83,402 common shares. A remaining balance of 2,113 RSUs is reported outstanding.

Positive

  • None.

Negative

  • None.
Insider KASINGER JAMES R.
Role General Counsel and Secretary
Sold 1,076 shs ($72K)
Type Security Shares Price Value
Sale Common Shares 1,076 $66.60 $72K
Exercise Restricted Stock Units 2,114 $0.00 --
Exercise Common Shares 2,114 $0.00 --
Holdings After Transaction: Common Shares — 83,402 shares (Direct); Restricted Stock Units — 2,113 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Includes 635 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KASINGER JAMES R.
(Last) (First) (Middle)
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
(Street)
BOSTON MA 02127
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel and Secretary
3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 10/13/2025 M 2,114 A (1) 84,478(2) D
Common Shares 10/14/2025 S 1,076(3) D $66.6 83,402 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 10/13/2025 M 2,114 (4) (4) Common Shares 2,114 (1) 2,113 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
2. Includes 635 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
4. This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CRSP disclose in this Form 4?

An officer reported settlement of 2,114 RSUs into common shares on 10/13/2025 and a sale of 1,076 shares on 10/14/2025.

How many shares were sold and at what price?

The filing shows 1,076 shares sold at $66.6 per share.

Why were the shares sold?

The sale was to cover tax withholding related to RSU vesting, mandated by the company’s RSU Settlement Policy.

What is the insider’s role at CRSP?

The reporting person is the company’s General Counsel and Secretary.

What is the insider’s direct share ownership after the transactions?

Direct beneficial ownership is reported as 83,402 common shares.

How many RSUs remain outstanding for the insider?

The filing lists 2,113 RSUs remaining outstanding.

Which dates are associated with these transactions?

RSUs settled on 10/13/2025; tax-related sale occurred on 10/14/2025.